prikaz prve stranice dokumenta Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2
  Download
PDF 978.69 KB
master's thesis
Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2
2024. urn:nbn:hr:152:372226
Lauš, Karla
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek

Cite this document

Lauš, K. (2024). Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2 (Master's thesis). Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek. Retrieved from https://urn.nsk.hr/urn:nbn:hr:152:372226

Lauš, Karla. "Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2024. https://urn.nsk.hr/urn:nbn:hr:152:372226

Lauš, Karla. "Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2024. https://urn.nsk.hr/urn:nbn:hr:152:372226

Lauš, K. (2024). 'Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2', Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, accessed 04 April 2025, https://urn.nsk.hr/urn:nbn:hr:152:372226

Lauš K. Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2 [Master's thesis]. Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek; 2024 [cited 2025 April 04] Available at: https://urn.nsk.hr/urn:nbn:hr:152:372226

K. Lauš, "Prevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2", Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, Osijek, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:152:372226

Please login to the repository to save this object to your list.
Metadata
TitlePrevalencija steatoze i fibroze jetre kod oboljelih od šećerne bolesti tipa 2
Title (english)Prevalence of liver steatosis and fibrosis in patients with type 2 diabetes mellitus
AuthorKarla Lauš
MentorSilvija Canecki Varžić (mentor)
Committee memberInes Bilić-Ćurčić (predsjednik povjerenstva)
Committee memberIvana Prpić-Križevac (član povjerenstva)
Committee memberSandra Šarić (član povjerenstva)
GranterJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Osijek
Defense date and country2024-07-11, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract
Cilj : Ispitati prevalenciju steatoze i firoze jetre kod oboljelih od šećerne bolesti tipa 2, ispitati povezanost steatoze i fibroze s kliničkim karakteristikama bolesnika kao i s razvitkom kardiovaskularnih komplikacija Nacrt studije: Presječna studija s povijesnim podatcima Ispitanici i metode: Ispitanici u ovom istraživanju bili su bolesnici sa šećernom bolesti tipa 2 koji su u jednogodišnjem razdoblju bili hospitalizirani na Zavodu za endokrinologiju, KBC-a Osijek. Isključni... More kriterij je bio druga etiologija jetrene bolesti (virusi, toksini, lijekovi). Rezultati: Od 142 ispitanika kod njih 78 (54,9 %) zabilježena je steatoza, dok je fibroza zabilježena kod 8 (5,6 %). Nije dokazana povezanost steatoze i fibroze sa razvitkom kardiovaskularnih komplikacija te sa indeksom tjelesne mase, dobi i trajanjem šećerne bolesti. Ispitanici sa steatozom pokazuju značajno više vrijednosti ALT-a (P < 0,001), a značajno niže vrijednosti leukocita (P = 0,04), CRP-a (P < 0,001) te fibrinogena (P = 0,01). Dok ispitanici sa fibrozom pokazuju značajno više vrijednosti PAI-1 (P = 0,03), ALT-a (P < 0,001), AST-a (P < 0,001) i GGT-a (P < 0,001), a značajno niže vrijednosti HDL-a (P = 0,01). Zaključak: Steatoza i fibroza jetre učestale su kod oboljelih od šećerne bolesti tipa 2. Provođenje probira na metabolički posredovanu masnu bolest jetre (MAFLD, engl. Metabolic dysfunction-associated fatty liver disease ) neinvazivnim dijagnostičkim testovima pomoglo bi otkrivanju bolesti u još reverzibilnoj fazi te smanjilo broj invazivnih procedura, odnosno biopsija. Less
Abstract (english)
Objective: To investigate the prevalence of steatosis and liver fibrosis in patients with type 2 diabetes mellitus (T2DM), and to examine the association of steatosis and fibrosis with clinical characteristics of the patients and with the development of cardiovascular complications. Study Design: Cross-sectional study with historical dana Subjects and Methods: The subjects in this study were patients with T2DM who were hospitalized in the Department of Endocrinology, Osijek... More General Hospital, during a one-year period. The exclusion criterion was other etiology of liver disease (viruses, toxins, drugs). Results: Steatosis was recorded in 78 (54.9%) of the 142 subjects, while fibrosis was recorded in 8 (5.6%). No association was found between steatosis and fibrosis with the development of cardiovascular complications, body mass index, age, and duration of diabetes. Subjects with steatosis showed significantly higher ALT values (P < 0.001), and significantly lower leukocyte (P = 0.04), CRP (P < 0.001), and fibrinogen (P = 0.01) values. While subjects with fibrosis showed significantly higher PAI-1 (P = 0.03), ALT (P < 0.001), AST (P < 0.001), and GGT (P < 0.001) values, and significantly lower HDL (P = 0.01) values. Conclusion: Steatosis and liver fibrosis are common in patients with T2DM. Screening for metabolically mediated fatty liver disease (MAFLD) with non-invasive diagnostic tests could help detect the disease in its still reversible phase and reduce the number of invasive procedures, i.e. biopsies. Less
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:152:372226
Study programmeTitle: University graduate study
Study programme type: university
Study level: graduate
Academic / professional title: magistar/magistra medicinsko laboratorijske dijagnostike (magistar/magistra medicinsko laboratorijske dijagnostike)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-12-17 12:04:38
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.